These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 22718483

  • 1. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 2. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 3. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, RITP study group.
    Lancet; 2015 Apr 25; 385(9978):1653-61. PubMed ID: 25662413
    [Abstract] [Full Text] [Related]

  • 4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct 25; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 5. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol; 2010 Oct 25; 85(4):329-34. PubMed ID: 20546023
    [Abstract] [Full Text] [Related]

  • 6. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.
    Am J Hematol; 2012 Mar 25; 87(3):321-3. PubMed ID: 22190262
    [Abstract] [Full Text] [Related]

  • 7. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct 25; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 8. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study Group.
    Ann Hematol; 2007 Dec 25; 86(12):871-7. PubMed ID: 17874322
    [Abstract] [Full Text] [Related]

  • 9. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.
    Am J Ther; 2013 Dec 25; 20(2):219-22. PubMed ID: 23466621
    [Abstract] [Full Text] [Related]

  • 10. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr 25; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 11. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun 25; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
    Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, Jean R, Kaplanski G, Harlé JR, Durand JM.
    Ann Hematol; 2012 Feb 25; 91(2):279-85. PubMed ID: 21710166
    [Abstract] [Full Text] [Related]

  • 13. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.
    Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Sánchez-Cárdenas M.
    Eur J Haematol; 2013 Jun 25; 90(6):494-500. PubMed ID: 23470153
    [Abstract] [Full Text] [Related]

  • 14. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov 25; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 15. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar 25; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 16. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B, Lindholm C, Pullerits R.
    Lupus; 2013 Jun 25; 22(7):664-74. PubMed ID: 23612795
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia].
    Sui T, Zhang L, Zhou ZP, Xue F, Ge J, Yang RC.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep 25; 32(9):583-6. PubMed ID: 22338149
    [Abstract] [Full Text] [Related]

  • 18. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar 25; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 19. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J.
    Nephrol Dial Transplant; 2012 May 25; 27(5):1910-5. PubMed ID: 22076431
    [Abstract] [Full Text] [Related]

  • 20. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
    D'Arena G, Capalbo S, Laurenti L, Del Poeta G, Nunziata G, Deaglio S, Spinosa G, Tarnani M, De Padua L, Califano C, Ferrara F, Cascavilla N.
    Eur J Haematol; 2010 Dec 25; 85(6):502-7. PubMed ID: 20846302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.